Cargando…

Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan

This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Ko, Takahashi, Kazuaki, Nagashima, Shintaro, E, Bunthen, Ouoba, Serge, Hussain, Md Razeen Ashraf, Akita, Tomoyuki, Sugiyama, Aya, Sakaguchi, Takemasa, Tahara, Hidetoshi, Ohge, Hiroki, Ohdan, Hideki, Kubo, Tatsuhiko, Ishikawa, Nobuhisa, Takafuta, Toshiro, Fujii, Yoshiki, Mimori, Michi, Okada, Fumie, Kishita, Eisaku, Ariyoshi, Kunie, Kuwabara, Masao, Tanaka, Junko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844052/
https://www.ncbi.nlm.nih.gov/pubmed/35165301
http://dx.doi.org/10.1038/s41598-022-04952-2
_version_ 1784651400231256064
author Ko, Ko
Takahashi, Kazuaki
Nagashima, Shintaro
E, Bunthen
Ouoba, Serge
Hussain, Md Razeen Ashraf
Akita, Tomoyuki
Sugiyama, Aya
Sakaguchi, Takemasa
Tahara, Hidetoshi
Ohge, Hiroki
Ohdan, Hideki
Kubo, Tatsuhiko
Ishikawa, Nobuhisa
Takafuta, Toshiro
Fujii, Yoshiki
Mimori, Michi
Okada, Fumie
Kishita, Eisaku
Ariyoshi, Kunie
Kuwabara, Masao
Tanaka, Junko
author_facet Ko, Ko
Takahashi, Kazuaki
Nagashima, Shintaro
E, Bunthen
Ouoba, Serge
Hussain, Md Razeen Ashraf
Akita, Tomoyuki
Sugiyama, Aya
Sakaguchi, Takemasa
Tahara, Hidetoshi
Ohge, Hiroki
Ohdan, Hideki
Kubo, Tatsuhiko
Ishikawa, Nobuhisa
Takafuta, Toshiro
Fujii, Yoshiki
Mimori, Michi
Okada, Fumie
Kishita, Eisaku
Ariyoshi, Kunie
Kuwabara, Masao
Tanaka, Junko
author_sort Ko, Ko
collection PubMed
description This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.). The targeted spike region is amplified by nested RT-PCR using in-house designed primer set hCoV-Spike-A and standard amplification protocol. Additionally, randomly selected 96 samples were also amplified using primer sets hCoV-Spike-B and hCoV-Spike-C. The negative amplified samples were repeated for second attempt of amplification by volume-up protocol. Thereafter, the amplified products were assigned for Sanger sequencing using corresponding primers. The positive amplification rate of primer set hCoV-Spike-A, hCoV-Spike-B and hCoV-Spike-C were 87.3%, 83.3% and 93.8% respectively for standard protocol and increased to 99.6%, 95.8% and 96.9% after second attempt by volume-up protocol. The readiness of genome sequences was 96.9%, 100% and 100% respectively. Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation. Moreover, 5 cluster cases with single mutation at N501S were firstly reported in Hiroshima. This study indicates the reliability and effectiveness of Sanger sequencing to screen large number of samples for the notable SARS-CoV-2 variants. Compared to the Next Generation Sequencing (NGS), our method introduces the feasible, universally applicable, and practically useful tool for identification of the emerging variants with less expensive and time consuming especially in those countries where the NGS is not practically available. Our method allows not only to identify the pre-existing variants but also to examine other rare type of mutation or newly emerged variants and is crucial for prevention and control of pandemic.
format Online
Article
Text
id pubmed-8844052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88440522022-02-16 Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan Ko, Ko Takahashi, Kazuaki Nagashima, Shintaro E, Bunthen Ouoba, Serge Hussain, Md Razeen Ashraf Akita, Tomoyuki Sugiyama, Aya Sakaguchi, Takemasa Tahara, Hidetoshi Ohge, Hiroki Ohdan, Hideki Kubo, Tatsuhiko Ishikawa, Nobuhisa Takafuta, Toshiro Fujii, Yoshiki Mimori, Michi Okada, Fumie Kishita, Eisaku Ariyoshi, Kunie Kuwabara, Masao Tanaka, Junko Sci Rep Article This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.). The targeted spike region is amplified by nested RT-PCR using in-house designed primer set hCoV-Spike-A and standard amplification protocol. Additionally, randomly selected 96 samples were also amplified using primer sets hCoV-Spike-B and hCoV-Spike-C. The negative amplified samples were repeated for second attempt of amplification by volume-up protocol. Thereafter, the amplified products were assigned for Sanger sequencing using corresponding primers. The positive amplification rate of primer set hCoV-Spike-A, hCoV-Spike-B and hCoV-Spike-C were 87.3%, 83.3% and 93.8% respectively for standard protocol and increased to 99.6%, 95.8% and 96.9% after second attempt by volume-up protocol. The readiness of genome sequences was 96.9%, 100% and 100% respectively. Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation. Moreover, 5 cluster cases with single mutation at N501S were firstly reported in Hiroshima. This study indicates the reliability and effectiveness of Sanger sequencing to screen large number of samples for the notable SARS-CoV-2 variants. Compared to the Next Generation Sequencing (NGS), our method introduces the feasible, universally applicable, and practically useful tool for identification of the emerging variants with less expensive and time consuming especially in those countries where the NGS is not practically available. Our method allows not only to identify the pre-existing variants but also to examine other rare type of mutation or newly emerged variants and is crucial for prevention and control of pandemic. Nature Publishing Group UK 2022-02-14 /pmc/articles/PMC8844052/ /pubmed/35165301 http://dx.doi.org/10.1038/s41598-022-04952-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ko, Ko
Takahashi, Kazuaki
Nagashima, Shintaro
E, Bunthen
Ouoba, Serge
Hussain, Md Razeen Ashraf
Akita, Tomoyuki
Sugiyama, Aya
Sakaguchi, Takemasa
Tahara, Hidetoshi
Ohge, Hiroki
Ohdan, Hideki
Kubo, Tatsuhiko
Ishikawa, Nobuhisa
Takafuta, Toshiro
Fujii, Yoshiki
Mimori, Michi
Okada, Fumie
Kishita, Eisaku
Ariyoshi, Kunie
Kuwabara, Masao
Tanaka, Junko
Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
title Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
title_full Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
title_fullStr Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
title_full_unstemmed Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
title_short Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
title_sort mass screening of sars-cov-2 variants using sanger sequencing strategy in hiroshima, japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844052/
https://www.ncbi.nlm.nih.gov/pubmed/35165301
http://dx.doi.org/10.1038/s41598-022-04952-2
work_keys_str_mv AT koko massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT takahashikazuaki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT nagashimashintaro massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT ebunthen massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT ouobaserge massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT hussainmdrazeenashraf massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT akitatomoyuki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT sugiyamaaya massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT sakaguchitakemasa massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT taharahidetoshi massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT ohgehiroki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT ohdanhideki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT kubotatsuhiko massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT ishikawanobuhisa massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT takafutatoshiro massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT fujiiyoshiki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT mimorimichi massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT okadafumie massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT kishitaeisaku massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT ariyoshikunie massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT kuwabaramasao massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan
AT tanakajunko massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan